Clinical Trial Update: CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CMV-TCIP directed Letermovir prophylaxis after allogeneic stem cell transplantation; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: University of California, Irvine | Conditions: CMV, Allogeneic Stem Cell Transplantation | Phase 2 | Status: RECRUITING